NEW YORK (GenomeWeb) — Nanosphere said today that it has been selected by HealthTrust to provide multi-target molecular diagnostic tests for nearly 1,400 acute care facilities that are part of the HealthTrust membership.

Under the agreement, HealthTrust's members will have access to purchase Nanosphere's portfolio of Verigene multiplex molecular diagnostics tests for infectious diseases, including assays for detecting infections of the bloodstream, respiratory tract, and gastrointestinal tract.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.